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Aims The potential of remote ischaemic conditioning (RIC) to ameliorate myocardial ischaemia-reperfusion injury (IRI)
remains controversial. We aimed to analyse the pre-clinical evidence base to ascertain the overall effect and vari-
ability of RIC in animal in vivo models of myocardial IRI. Furthermore, we aimed to investigate the impact of differ-
ent study protocols on the protective utility of RIC in animal models and identify gaps in our understanding of this
promising therapeutic strategy.
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Methods
and results
Our primary outcome measure was the difference in mean infarct size between RIC and control groups in in vivo
models of myocardial IRI. A systematic review returned 31 reports, from which we made 22 controlled comparisons
of remote ischaemic preconditioning (RIPreC) and 21 of remote ischaemic perconditioning and postconditioning
(RIPerC/RIPostC) in a pooled random-effects meta-analysis. In total, our analysis includes data from 280 control ani-
mals and 373 animals subject to RIC. Overall, RIPreC reduced infarct size as a percentage of area at risk by 22.8%
(95% CI 18.8–26.9%), when compared with untreated controls (P< 0.001). Similarly, RIPerC/RIPostC reduced infarct
size by 22.2% (95% CI 17.1–25.3%; P< 0.001). Interestingly, we observed significant heterogeneity in effect size
(T2¼ 92.9% and I2¼ 99.4%; P< 0.001) that could not be explained by any of the experimental variables analysed by
meta-regression. However, few reports have systematically characterized RIC protocols, and few of the included
in vivo studies satisfactorily met study quality requirements, particularly with respect to blinding and randomization.
....................................................................................................................................................................................................
Conclusions RIC significantly reduces infarct size in in vivo models of myocardial IRI. Heterogeneity between studies could not
be explained by the experimental variables tested, but studies are limited in number and lack consistency in quality
and study design. There is therefore a clear need for more well-performed in vivo studies with particular emphasis
on detailed characterization of RIC protocols and investigating the potential impact of gender. Finally, more studies
investigating the potential benefit of RIC in larger species are required before translation to humans.
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1. Introduction
Myocardial ischaemia-reperfusion injury (IRI) describes the deleterious
consequences of several pathological processes and cardiac
interventions. Most commonly, it is caused by thrombotic occlusion of
the coronary artery in ST-segment elevation myocardial infarction
(STEMI) and subsequent reperfusion by primary percutaneous coronary
intervention (PPCI), but it may result from a range of elective and
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emergent causes of myocardial ischaemia, including cardiopulmonary by-
pass and spontaneous reperfusion of STEMI. Despite constantly improv-
ing medical and surgical practice, myocardial IRI remains associated with
significant morbidity and mortality. For example, in STEMI and despite
PPCI, 30 day, 1 year, and 5 year cardiac mortality remains 7.3%, 8.4%,
and 13.8%, respectively.1
It has been demonstrated that myocardium can be protected from le-
thal IRI by the application of multiple brief cycles of ischaemia and reper-
fusion to an organ or tissue remote from the heart, either before, during,
or after the index ischaemia (preconditioning, perconditioning, or post-
conditioning, respectively). Limb remote ischaemic conditioning (RIC) is
a cheap, non-invasive intervention that, since its inception in 1997,2 has
been successfully demonstrated in several pre-clinical studies of myocar-
dial IRI. Subsequently, several Phase II, proof-of-concept clinical studies
have translated these findings to variety of clinical settings, albeit fre-
quently using cardiac enzymes as surrogate markers of cellular injury,
including coronary artery bypass surgery (CABG),3–6 elective abdominal
aortic aneurysm repair,7,8 elective cervical decompression surgery,9
elective PCI,10 and in PPCI for STEMI.11–13
However, more recent, large clinical-endpoint studies of RIC in car-
diac surgery have been neutral.14,15 Although cardiac surgery may be an
inappropriate setting for RIC, given the small peri-operative injury and
lack of injurious warm ischaemia-reperfusion,16 these findings have
prompted an interrogation of the pre-clinical evidence base for RIC and
a perceived lack of systematic pre-clinical characterization of the optimal
RIC stimulus.16 This is in contrast to direct ischaemic conditioning that,
despite being limited by the necessity to intervene before the index is-
chaemia, has been thoroughly characterized.17
Well-designed animal studies can provide useful information on rele-
vant factors that may influence outcome. This comprehensive systematic
review and meta-analysis scrutinizes basic studies of RIC in in vivo animal
models of myocardial IRI. Our aim was to ascertain the overall effect and
variability of RIC in this context, compared with control (sham procedure
or no treatment). We further aimed to investigate determinants of effi-
cacy, including variables such as RIC protocol and use of supplementary
oxygen. Our hypothesis was that study quality and publication bias would
result in over-estimation of the effect size associated with RIC.18,19
2. Methods
2.1 Systematic review
The systematic review was performed in accordance with Preferred
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)
guidelines.20 A literature search was conducted on 21 August 2015 by
J.P. Keywords and MeSH terms were used to search Medline and
Embase (via OVID) between 1997 and present, and further studies were
identified by consultation with experts in the field. Details of the search
strategy are available in the Supplementary material online, Search strat-
egy section.
Study eligibility criteria were defined using the PICOS approach.21 In
vivo animal studies were included and were eligible if they investigated
the effect of limb RIC (pre, per, or post) vs. a control (sham procedure
or no treatment) on myocardial infarct size (IS), as measured using tetra-
zolium chloride (TTC),22 in any mammalian species, regardless of study
design. Transient infra-renal aortic occlusion was considered as bilateral
hind limb ischaemia.
Studies were excluded if they did not include or report absolute myo-
cardial IS as a percentage of area at risk (AAR, defined as the myocardial
tissue within the vascular territory that is distal to occluded artery and, if
not reperfused, is at risk of irreversible ischaemic death).23 The AAR
varies depending on the exact position of the LAD suture and variable
LAD anatomy. IS has a strong positive correlation with AAR and there-
fore, without correction, a small AAR could create false-positive results
for cardioprotection, and vice versa.24 Furthermore, studies were
excluded if they specifically investigated only the ‘second window’ of car-
dioprotection (RIC to infarction interval> 1 h),25–27 if RIPostC was initi-
ated more than 10 min after reperfusion (after which it is generally
believed unlikely to be effective),28 if the animals had co-morbidities, if IS
was only measured using a method other than TTC, or if they investi-
gated the impact of RIC in the context of heart transplant. Groups in
which RIC was administered in combination with another conditioning
protocol (local conditioning, for example), or with pharmacological
treatments known to have cardioprotective effects, were excluded.
Finally, studies investigating neonatal animals were excluded to ensure
clinical relevance to IRI.
Reports were excluded if they were not available in English and a pub-
lication date restriction of 1997–present was imposed in view of the first
publication of the efficacy of RIC in the limb.2 Review articles, abstract
articles, unpublished material, and ongoing studies were excluded.
Retrieved records were screened for eligibility using the title and ab-
stract, followed by the full text. Eligibility assessment was performed in-
dependently in an un-blinded, standardized manner by D.B. and J.P.
Disagreements were resolved by examining the full text of the article or
by consensus between reviewers in all cases.
Data were independently extracted by two authors (D.B. and J.P.)
using pre-defined data fields. Disagreements were resolved by consensus
in all cases. We attempted to acquire key missing information by con-
tacting the report authors by e-mail.
Variables for which data were sought were developed using the
PICOS approach.4,21 Data items were chosen according to experimental
variables with evidence for an effect on myocardial IRI as these were
considered likely to impact on the efficacy or RIC, and variables that we
considered of potential importance. Full list of data items and assump-
tions is available in the Supplementary material online, Data items
section.
2.2 Meta-analysis
We defined the primary outcome as the weighted (unstandardized)
mean difference (WMD) between ISs in the RIC and control groups.
WMD was used as all data were presented in the same units and it gives
a biologically relevant value. In each publication, we identified all inde-
pendent comparisons of IS/AAR% in RIC vs. control groups. Where a
study made multiple comparisons to the same control group, the size of
the control group was corrected for the number of comparisons made
(n/number of comparisons).29 The secondary outcome was the effect of
five pre-defined experimental variables, which we considered most likely
to impact on the efficacy of RIC, on WMD.
Comparisons were grouped according to their use of either remote is-
chaemic preconditioning (RIPreC) or remote ischaemic perconditioning
and postconditioning (RIPerC/RIPostC). This is due to temporal differ-
ences in their application that, despite not necessarily occurring via differ-
ent mechanistic pathways,30 have different clinical utility. Specifically,
RIPerC/RIPostC are clinically applicable to STEMI, whereas RIPreC is not.
Subsequent analysis was performed for each group separately.
For each independent comparison, we calculated the effect size as a
raw difference in IS/AAR% means (the mean of the control groups minus
the mean of the experimental group) and the corresponding 95%
2 D.I. Bromage et al.
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..confidence interval (CI). To account for anticipated heterogeneity, we
pooled effect sizes using random-effects meta-analysis, which considers
the within-study and between-study variability and weights each study
accordingly. Heterogeneity was quantified using I2 and T2 statistics.29,31
Studies with missing data on any of the pre-defined experimental vari-
ables were excluded from the meta-analysis.
Subgroup analyses were performed using univariate meta-regressions
to explore which experimental factors and quality indicators contribute
to heterogeneity. The percentage of between-study variance explained
by variables of interest was assessed using the T2 and adjusted R2 statis-
tics. The significance level was adjusted according to the number of com-
parisons using the Holm–Bonferroni method and results were
considered significant when P< 0.01.32 Classification of subgroups is
given in the Supplementary material online, Summary measures section.
Sensitivity analysis was performed to assess the robustness of our
findings by performing an additional analysis for both the primary and the
secondary endpoints using the standardized mean difference (SMD; the
mean of the control group minus the mean of the RIC group, divided by
the pooled SD of the two groups). We performed a stratified meta-
analysis by subgroup to validate the results obtained by meta-regression.
All analyses were pre-specified and performed using STATA/SE, ver-
sion 13.1 (StataCorp, College Station, TX, USA); GraphPad Prism ver-
sion 5.00 for Windows (La Jolla, CA, USA) was used in the production of
figures.
2.3 Risk of bias
We used a component approach to assess study quality, based on the
study report, using the ‘Animal Research: Reporting of In Vivo
Experiments’ (ARRIVE) guidelines and a 12-item quality score.33–35 The
derivation of the 12-item quality score is given in the Supplementary ma
terial online, Table S3; and the methodological features evaluated for
each study are given in the Supplementary material online, Tables S4 and
S5. Study quality was assessed independently from data extraction and
between assessors in an un-blinded, standardized manner by two re-
viewers (O.Z. and N.B.). Disagreements were resolved by consensus in
all cases. We assessed the relationship between study quality and the
overall effect of RIC on IS/AAR% using meta-regression, as described
above.
Potential publication bias was assessed by visual inspection of a funnel
plot for asymmetry, and Egger’s regression analysis for small study ef-
fects. No protocols were available with which to examine for selective
reporting; however, the methods and results sections of all included
studies were carefully compared for inconsistencies.
3. RESULTS
3.1 Study selection
Our search returned 539 records, including 169 duplicate reports (con-
sisting of reports returned by both Medline and Embase). In total, 370 re-
ports underwent title and abstract screening, which resulted in 256
exclusions. The remaining 114 reports were retrieved for detailed full
text evaluation. Eighty-three articles were excluded, 66 due to failing to
meet the inclusion criteria, 12 were abstracts, and two were not retriev-
able. Of the remaining 34 reports (studies), three were missing data on
one or more important experimental variables that we were unable to
retrieve by contacting the study authors, and were consequently
excluded. These studies are referenced in the Supplementary material
online, References section. The remaining 31 studies were included in the
quantitative synthesis (Figure 1). All included studies and their main char-
acteristics are reported in the Supplementary material online, Data ex-
traction table.
3.2 Meta-analysis
From the 31 included reports, we extracted data on 43 controlled com-
parisons of RIC in models of myocardial IRI. These were split into 22
comparisons investigating RIPreC, and 21 comparisons investigating
RIPerC/RIPostC. In total, our analysis includes data from 280 control ani-
mals and 373 animals undergoing RIC. In the RIPreC group, conditioning
reduced IS/AAR% by 22.8% (95% CI 18.8–26.9%) when compared with
untreated controls (P< 0.001; n¼ 22 comparisons, Figure 2A). Significant
heterogeneity was observed (T2¼ 89.2 and I2¼ 99.1%; P< 0.001). In
the RIPreC/RIPostC group, conditioning reduced IS/AAR% by 22.2%
(95% CI 17.1–25.3%) when compared with untreated controls
(P< 0.001; n¼ 21 comparisons, Figure 2B). Again, significant heterogen-
eity was observed (T2¼ 90.9 and I2¼ 99.5%; P< 0.001).
We investigated potential experimental sources of the observed het-
erogeneity using meta-regression analysis with IS/AAR% as the depend-
ent variable, and did not find any significant associations with efficacy of
RIC (Figure 3A and B).
3.3 Risk of bias
Reports achieved a median ARRIVE guidelines score of 14 (inter-quartile
range 12–14) out of 20 and a median 12-item quality score of 7 (inter-
quartile range 6–8; Figure 4). A full breakdown of the scores is given in
the Supplementary material online, Tables S7 and S8. Meta-regression
indicated that study quality according to either the ARRIVE guidelines
score or to a 12-item quality score was not associated with the overall
effect (P¼ 0.317 and P¼ 0.846, respectively).
Overall, studies performed particularly poorly in several important
areas of experimental design. For example, with respect to the ARRIVE
guidelines only 16% reported sample size calculation, 23% reported ran-
domization of animals to experimental groups, 23% defined the primary
Figure 1 Flow chart of the study selection process. A systematic re-
view yielded 539 reports. After removal of duplicates and the applica-
tion of inclusion and exclusion criteria, 31 studies were included in the
meta-analysis.
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Figure 2 Forest plots of meta-analysis of conditioning efficacy in (A) RIPreC and (B) RIPerC/RIPostC. Forest plots of the effect of (A) RIPreC and (B)
RIPerC/RIPostC on IS/AAR%, pooled using random-effects meta-analysis; 22 and 21, respectively, controlled comparisons were included, amounting to data
from 280 control animals and 373 animals undergoing RIC.
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.experimental outcome, and 29% reported detail of adverse events dur-
ing experiments (Figure 4A). Regarding the 12-item quality score, only
32% of studies reported measurement of blood oxygen saturation, 13%
reported measurement of blood pressure during the in vivo protocol,
and 10% performed blinded application of the conditioning protocol
(Figure 4B). Notably, only 38% of studies performed a blinded assessment
of outcome.
The impact of publication bias on the overall effect was assessed by
visual analysis of the funnel plot, which suggested that small and negative
studies might be under-represented (Figure 5). However, in Egger’s re-
gression test the null-hypothesis of no small-study effect was not re-
jected at P¼ 0.216 (estimated bias coefficient 3.756 2.98 SE).
3.4 Sensitivity analysis
When re-running our analysis using the SMD, all results were similar to
those found using the WMD. We found a highly significant (P< 0.001)
overall effect of RIPreC (SMD of 11.06; 95% CI 8.52–13.60), as well as a
similar level of heterogeneity (I2¼91.1%). None of the experimental
variables was significant after correction by multiple comparison. For
RIPerC/RIPostC, all results using the SMD were likewise similar to those
found using the WMD. We found a highly significant (P< 0.001) overall
effect (SMD of 13.14; 95% CI 10.51–15.77) and similar heterogeneity
(I2¼93.3%). None of the experimental variables was significant after
correction by multiple comparison.
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Figure 3 Impact of experimental factors on the efficacy of (A) RIPreC and (B) RIPerC/RIPostC. WMD and the corresponding 95% CI for each variable
were obtained by subgroup stratification. However, the reported P-value was obtained by meta-regression to reduce false-positive findings. Studies that
used either mice or rats were grouped as ‘small animals’, and those using rabbits or pigs were grouped as ‘large animals’. A P-value of< 0.01 was considered
significant.
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..4. Discussion
Our major finding is that both RIPreC and RIPerC/RIPostC have a large
beneficial effect of both on IS. This finding is based on a comprehensive
systematic review, including over 650 animals. However, there were
relatively few pre-clinical studies investigating RIC and even fewer sys-
tematically characterizing the protocol, which limited our analysis.
Furthermore, we found inconsistency in the design of pre-clinical RIC
studies with very few that were randomized effectively, included both
male and female animals, and were double blinded with respect to pro-
cedure and outcome, which highlights the need for further well-
designed, pre-clinical studies of RIC.
These are important findings in the context of recent pessimism re-
garding RIC as a genuine cardioprotective phenomenon.36,37 Clinical tri-
als investigating the efficacy of RIC in myocardial IRI have had mixed
results,11,14 which has been attributed to clinical variables, including pro-
pofol administration.36 However, each of the factors described above
may influence outcome through lack of generalizability or unconscious
bias,19 and therefore indirectly impact upon attempts to translate RIC to
humans in clinical trials.16
4.1 Determinants of RIC
Interestingly, we found high levels of heterogeneity between studies. To
investigate whether study protocol could account for the observed het-
erogeneity, and to elucidate the determinants of efficacy of RIC, we
assessed the impact of experimental variables on effect size using a
meta-regression analysis. This approach has been successfully applied to
several promising pre-clinical interventions to date. For example, Lim
et al.38 were able to demonstrate that ciclosporin was not effective at
limiting myocardial IS in pig models of IRI, compared with small animal
models. This finding might be important in the context of a subsequent
neutral clinical study of ciclosporin before reperfusion in patients with
STEMI.39 Therefore, finding the parameters responsible for heterogen-
eity can guide pre-clinical and clinical study design.
However, none of the tested experimental variables, which included
species, cycle duration, number of cycles, number of conditioned limbs
and the use of supplementary oxygen, was associated with effect size. In
a recent analysis of pre-clinical studies of local ischaemic preconditioning,
which included limited analysis of RIC, species (rodent vs. non-rodents)
accounted for a substantial amount of the observed heterogeneity.17
Although we found no significant association between animal size
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0
Title
Abstract
Background
Objectives
Ethical statement
Study design
Experimental prcedures
Experimental animals
Housing and Husbandary
Sample size
Allocating animals to experimental group
Experimental outcomes
Statistical methods
Baseline data
Numbers analysed
Outcomes and estimation
Adverse events
Interpretation/scientific implications
Generalizability/translation
Funding Yes
No
0 50 10
0
Publication in peer-review journal
Randomization
Blinded assessment of outcome
Complience with regulatory requirement
Method of confirmation of ischemia
Statement of control of temperature
Statement of recording ECG
Measurement of PaO2 or SaO2
Statement of measurement of BP
Sample size calculation
Blinded application of RIC
Statement of conflict of interest
Passed study quality criteria?
ARRIVE guidelines
Study quality score
Passed study quality criteria?
A
B
Figure 4 Reporting of study quality indicators. Study quality was assessed using the ARRIVE guidelines on reporting in vivo experiments (A) and a 12-item
quality score (B). Values are expressed as the percentage of studies reporting each quality indicator.
6 D.I. Bromage et al.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
(rodents vs. non-rodents), there was a pattern of increased efficacy of
RIPreC in large animals.
Wever et al.17 also describe no association between effect size and
the number, timing and duration of cycles, which is reflected in this study.
Specifically, we found 1, 3 and 4 cycles to be equally effective.
Conversely, in one of the few neutral comparisons in our analysis, Lu
et al.40 utilized a protocol consisting of one cycle of 5 min RIPreC.
Interestingly, this amounts to the lowest total ischaemic ‘dose’ (a func-
tion of cycle number and duration) of any study of RIPreC. Amongst the
RIPerC/RIPostC studies, only Li et al.41 applied one cycle of 5 min limb is-
chaemia and reported a relatively modest, albeit significant, effect
(WMD 14.35%, 95% CI 13.03–15.67%). Others, including Mastitskaya
et al.,42 have applied a single cycle of longer duration and achieved
greater protection. It is therefore plausible that ischaemic ‘dose’ or bur-
den, rather than cycle number or duration alone, is the dependent vari-
able, but very few studies have examined this systematically in vivo. An
exploratory analysis of the present data demonstrated no such associ-
ation (data not shown); however this was limited by a narrow distribu-
tion of total ischaemic times in our dataset. Interestingly, a dose-
dependent effect of RIPreC has been observed, with greater cardiopro-
tection after 10 or 15 min compared with 5 min continuous infra-renal
aortic occlusion.43 In a study comparing bilateral and unilateral RIPreC in
protection against renal IRI, bilateral was found to be more effective.44
Taken together, this may suggest that total ischaemic dose is important,
but this needs testing in specifically designed experiments.
Furthermore, there may be an upper limit to what is an effective is-
chaemic dose. A recent characterization of the RIC protocol ex vivo re-
ported that four and six, but not eight, cycles of RIC were protective in
mice.45 Similarly, although 5 min or 10 min limb ischaemia protected
against subsequent liver injury, 30 min and 60 min actually increased in-
jury.46 This issue is worthy of further attention, particularly using a more
realistic setting of aged animals with co-morbidities. This may suggest a
therapeutic window for RIC but there is very limited pre-clinical evi-
dence, in contrast to direct ischaemic conditioning where the number of
cycles is demonstrably important,17 and it is clear that detailed
characterization of study protocol in vivo is urgently necessary in order
to answer these questions.
After a period of limb ischaemia, it has been assumed that reperfusion
is necessary, either to wash out the putative humoral factor or because
reperfusion-induced ROS may be necessary to activate signalling path-
ways. Additionally, some studies have suggested that reactive hyper-
aemia is an important factor in the response.47 However it is worth
bearing in mind that the original description in rabbits, where RIPreC
was achieved by 55–65% stenosis of the femoral artery in combination
with rapid electrical stimulation of the gastrocnemius muscle for 30 min,
did not actually involve reperfusion.2 This appears to support the hy-
pothesis that multiple mechanisms are involved.48
Similarly, our analysis supports the finding of Wever et al.17 of no asso-
ciation with the number of limbs conditioned. Johnsen et al.45 further re-
ported that 2 and 5 min, in contrast to 10 min, cycles were beneficial in
mice. This remains consistent with the concept of a therapeutic window
of RIC but there is a paucity of in vivo experimental data relating to the
precise RIC protocol. Our analysis demonstrated 10 min cycles to be
equally effective as 5 min cycles, albeit only in larger species as no studies
in our meta-regression used 10 min cycles in mice. We also noticed a
pattern of reduced efficacy in RIPreC/RIPostC studies using two limbs in-
stead of one, which may exceed the therapeutic window. However, this
finding was not statistically significant and should only be considered hy-
pothesis-generating.
The use of supplementary oxygen in acute myocardial infarction is
controversial,49 but the role of supplementary oxygen in RIC has not, to
our knowledge, been investigated. It could be hypothesized that RIC is
driven by cellular hypoxia in the conditioned limb which, at least in part,
might be alleviated by ventilation with supplementary oxygen. However,
despite finding the conditioning of animals with and without oxygen to
be equally effective, there was a pattern of increased efficacy in animals
ventilated with supplementary oxygen in the RIPreC comparisons. This
has not been specifically investigated but our results would suggest fur-
ther investigation is warranted.
Furthermore, there is evidence that the degree of cardioprotection
conferred by RIC is proportional to the duration of index ischaemia.
Specifically, Kleinbongard et al.50 demonstrated longer ischaemic times
to be associated with a greater efficacy of RIC, albeit in a study of patients
undergoing CABG, which may be related to a greater target for protec-
tion. In an exploratory analysis, we found no statistical effect of index is-
chaemic time (see Supplementary material online, Table S5 and S6);
however, there was a pattern of reduced efficacy of RIC at longer ischae-
mic durations in RIPreC but not RIPerC/RIPostC. This might suggest an
important role for the timing of intervention, but should be interpreted
with caution in view of the limited number of comparisons available after
stratification according to study protocol.
There were several experimental variables that were of considerable
interest but that lacked sufficient power for statistical analysis. For ex-
ample, it has been suggested that propofol interferes with the develop-
ment of RIC,51,52 and it has been implicated as a potential reason for the
apparent lack of translation of RIC.53 Interestingly, we observed studies
where propofol (together with either opioid analgesia6 pancuronium)
was administered to have effect sizes above the mean.54,55
Furthermore, studies reporting the use of mixed gender experimental
groups reported apparently smaller effect sizes, and one of the few neutral
studies was performed only in female animals.56 Gender can potentially im-
pact upon IRI possibly due to the cardioprotection conferred by oestro-
gen,57,58 and potential temporal variability in cardioprotection as a result of
the oestrous cycle of female rats.59 However, investigation of the role of
Figure 5 Assessment of publication bias. A funnel plot comparing
treatment effect to a measure of study size (precision of the effect esti-
mate). The vertical line represents the mean effect size. This plot was
assessed visually, with further analysis of publication bias performed
using Egger’s regression test.
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gender is conspicuously absent from pre-clinical studies of RIC and these
qualitative data require further testing in formal, well-designed studies.
An important result of this study is the need for more pre-clinical
characterization of RIC, which as well as the aforementioned variables
should include the potential role of occlusion technique (arterial clamp-
ing vs. external compression), which may be important due to the pos-
sible involvement of limb collaterals,60 the putative effect of shear stress
in RIC,47 and the role of pre-treatment with heparin, which has been re-
ported to be cardioprotective in the context of IRI.61–65 Likewise, it has
been hypothesized that the interval between the conditioning stimulus
and the onset of index ischaemia might be an important determinant of
the efficacy of remote preconditioning.16
A further consideration is the impact of co-morbidities and co-
medications on the efficacy of RIC. The animal models used in pre-
clinical studies frequently do not reflect the complex risk factor, co-
morbidity and pharmaceutical profile of humans with cardiovascular dis-
ease,66,67 which may impede the development of RIC. For example,
Jensen et al.68 treated isolated perfused rabbit hearts subjected to IRI
with plasma dialysate from diabetic patients treated with RIC. They were
unable to confer cardioprotection using dialysate from patients with per-
ipheral neuropathy compared with non-diabetic patients and diabetic pa-
tients without neuropathy. Baranyai et al.69 similarly found that acute
hyperglycaemia abrogated the beneficial effect of RIPerC in Wistar rats.
However, despite considerable investigation of these features in local is-
chaemic preconditioning (reviewed by Ferdinandy et al.70), there is little
experimental data relating to these factors in the context of RIC. Indeed,
animals with co-morbidities were specifically excluded from the present
analysis due to the small number of studies available. Nonetheless, co-
morbidities should be considered when investigating the optimum
protocol for the delivery of RIC.
4.2 Risk of bias
Poor methodological quality and publication bias can result in over-
estimation of effect size.71–73 In turn, this can engender enthusiasm about
the benefit of a treatment where, in fact, none exists. It is therefore es-
sential to examine the impact of study quality on size of effect, to which
end we found no statistical relationship using meta-regression.
However, we made some interesting observations. Aspects of the re-
port relating to the experimental procedure, including control of tem-
perature and recording of the ECG, were generally well reported.
However, there was generally poor observation of the ARRIVE guide-
lines, particularly in relation to reporting of sample size calculations, ran-
domization, blinding and adverse events, which can result in selective
exclusion. For example, in an interesting meta-analysis of systematic re-
views, Hirst et al.74 reported that failure to randomize significantly
increased effect size. Furthermore, appropriate monitoring of experi-
mental animals, including recording of blood oxygen saturation and
blood pressure, was poorly reported. These facets are clearly essential
to ensure good quality research and were a central tenet of a recent pos-
ition paper on improving the pre-clinical assessment of novel cardiopro-
tective therapies.19 In some cases, these omissions will represent
inadequate reporting but in others it is likely that these crucial elements
of study design were not performed. We elected not to analyse each
quality criterion independently due to insufficient reporting and to avoid
false-positive findings due to multiple comparisons. However, poor ad-
herence to certain quality criteria may account for the heterogeneity
observed in this meta-analysis.
Finally, our assessment of publication bias by visual analysis of the fun-
nel plot suggested that small, neutral studies may be under-represented;
however, this did not statistically impact on the overall effect size, which
is reassuring.
4.3 Limitations
The validity of this meta-analysis is contingent upon the quality of re-
porting of the included studies. Unpublished studies and those with
missing data could not be included in the meta-analysis, and others
did not meet important quality criteria including poor information re-
garding statistical analysis and blinding. However, the absence of a
statistical impact from study quality or publication bias is reassuring in
this regard. We were limited by being unable to consider manuscripts
not available in English and we acknowledge that we did not carry out
a systematic literature review to determine which experimental vari-
ables to include in our analyses, which might be subject to selection
bias. A relatively small number of studies were included in the meta-
analysis, thereby limiting the power of the study, which was further af-
fected by multiple comparisons within individual studies; however,
we elected to include all comparisons to avoid selection bias. Meta-
regression is inherently limited; however, to ensure this was as robust
as possible we performed a stratified meta-analysis by subgroup that
yielded similar results, including a highly significant overall effect of
RIC, significant heterogeneity, and no effect of any of the experimen-
tal variables we included in our model.
5. Recommendations and
conclusions
This systematic review and meta-analysis of pre-clinical in vivo studies of
myocardial IRI demonstrates a significant and highly reproducible benefi-
cial effect of RIC. This effect was highly heterogeneous, a finding that may
be due to un-measurable, multifactorial differences between individual
experimenters and laboratories. However, importantly, in vivo studies to
date suggest the optimal RIC stimulus has not yet been identified. There
was a paucity of pre-clinical characterization of the RIC protocol and
poor reporting of quality indicators. This is important not so the proto-
col can be translated to humans, but in order to understand the import-
ant parameters and/or markers that will facilitate optimization of the
protocol in humans.
There has been a great deal of debate regarding neutral clinical
studies of RIC.16,36 However, before we try to understand these fail-
ings and design future studies it is essential to fully describe RIC in
pre-clinical experiments. At present, studies variably (and apparently
randomly) apply the intervention to one or two limbs, for varying
periods of time, with a variable number of cycles and with inconsist-
ent timing with respect to the injurious ischaemic episode. To this
end, we have identified a need for more, well-performed studies with
a focus on characterization rather than detailed elucidation of mech-
anisms. In particular, these should concentrate on investigating the
potential impact of gender and the number, timing and duration of
cycles on the efficacy of RIC. These aims would be greatly aided by
the identification of a biomarker or a critical physiological param-
eter(s) that correlates with protection. More studies investigating the
potential benefit of RIC in larger species are required before transla-
tion to humans and we highlight the potential role of supplementary
oxygen as particularly interesting for exploration. Finally, future re-
search should focus on investigating other potential reasons for neu-
tral clinical studies of RIC, including co-morbidities and adjunctive
therapies.
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